Fludarabine based combinations are highly effective as first-line or salvage treatment in patients with Waldenström macroglobulinemia

Leukemia and Lymphoma

Volumn 51, Issue 12, 2010, Pages 2188-2197

  Peinert, Stefan ^a,e,f   Tam, Constantine S ^b   Prince, H Miles ^a,c,e   Scarlett, John ^d   Wolf, Max M ^a,c,e   Januszewicz, E Henry ^a,c,e   Westerman, David ^a,e   Seymour, John F ^a,e  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b St Vincent's Health Melbourne ^*  (Australia)

^c CABRINI INSTITUTE   (Australia)

^d LATROBE REGIONAL HOSPITAL   (Australia)

^e UNIVERSITY OF MELBOURNE   (Australia)

^f Ernst von Bergmann Clinic   (Germany)

Author keywords

fludarabine; nucleoside analog; outcome; treatment; Waldenstrm macroglobulinemia

Indexed keywords

COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; MITOXANTRONE; RITUXIMAB; VALACICLOVIR;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ANTIBIOTIC PROPHYLAXIS; ARTICLE; CANCER RISK; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; DRUG EFFICACY; DRUG FEVER; FEMALE; FOLLOW UP; HERPES ZOSTER; HUMAN; INFECTION; LIVER TOXICITY; MALE; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; OVERALL SURVIVAL; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SALVAGE THERAPY; SURVIVAL RATE; THROMBOCYTOPENIA; TREATMENT RESPONSE; WALDENSTROEM MACROGLOBULINEMIA;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; RETROSPECTIVE STUDIES; SALVAGE THERAPY; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VIDARABINE; WALDENSTROM MACROGLOBULINEMIA;

EID: 78650067819     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2010.524326     Document Type: Article

References (41)

1. Swerdlow SH, Campo E, Harris NL, et al. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon: IARC; 2008.
2. Herrinton L, Weiss N. Incidence of Waldenstroms macroglobulinemia. Blood 1993;82:3148-3150.
3. Dimopoulos MA, Panayiotidis P, Moulopoulos LA, Sfikakis P, Dalakas M. Waldenstroms macroglobulinemia: clinical features, complications, and management. J Clin Oncol 2000; 18:214-226.
4. Ghobrial IM, Fonseca R, Gertz MA, et al. Prognostic model for disease-specific and overall mortality in newly diagnosed symptomatic patients with Waldenstrom macroglobulinaemia. Br J Haematol 2006;133:158-164.
5. Morel P, Duhamel A, Gobbi P, et al. International prognostic scoring system for Waldenstroms macroglobulinemia. Blood 2009;113:4163-4170.
6. Dimopoulos MA, Gertz MA, Kastritis E, et al. Update on treatment recommendations from the Fourth International Workshop on Waldenstroms Macroglobulinemia. J Clin Oncol 2009;27:120-126.
7. Facon T, Brouillard M, Duhamel A, et al. Prognostic factors in Waldenstroms macroglobulinemia: a report of 167 cases. J Clin Oncol 1993;11:1553-1558.
8. Kyle RA, Greipp PR, Gertz MA, et al. Waldenströms macroglobulinaemia: a prospective study comparing daily with intermittent oral chlorambucil. Br J Haematol 2000;108:737-742.
9. Treon SP, Agus DB, Link B, et al. CD20-directed antibodymediated immunotherapy induces responses and facilitates hematologic recovery in patients with Waldenstroms macroglobulinemia. J Immunother 2001;24:272-279.
10. Dimopoulos MA, Zervas C, Zomas A, et al. Treatment of Waldenstroms macroglobulinemia with rituximab. J Clin Oncol 2002;20:2327-2333.
11. Ghobrial IM, Fonseca R, Greipp PR, et al. Initial immunoglobulin M flare after rituximab therapy in patients diagnosed with Waldenstrom macroglobulinemia. Cancer 2004; 101:2593-2598.
12. Treon SP, Branagan AR, Hunter Z, Santos D, Tournhilac O, Anderson KC. Paradoxical increases in serum IgM and viscosity levels following rituximab in Waldenstroms macroglobulinemia. Ann Oncol 2004;15:1481-1483.
13. Buske C, Hoster E, Dreyling M, et al. The addition of rituximab to front-line therapy with CHOP (R-CHOP) results in a higher response rate and longer time to treatment failure in patients with lymphoplasmacytic lymphoma: results of a randomized trial of the German Low-Grade Lymphoma Study Group (GLSG). Leukemia 2008;23:153-161.
14. Ioakimidis L, Patterson C, Hunter Z, et al. Comparative outcomes following CP-R, CVP-R, and CHOP-R in Waldenstro ms macroglobulinemia. Clin Lymphoma Myeloma 2009; 9:62-66.
15. Delannoy A, Ferrant A, Martiat P, Bosly A, Zenebergh A, Michaux JL. 2-Chlorodeoxyadenosine therapy in Waldenstroms macroglobulinaemia. Nouv Rev Fr Hematol 1994;36: 317-320.
16. Dhodapkar MV, Jacobson JL, Gertz MA, et al. Prognostic factors and response to fludarabine therapy in patients with Waldenstrom macroglobulinemia: results of United States intergroup trial (Southwest Oncology Group S9003). Blood 2001;98:41-48.
17. Dimopoulos MA, Kantarjian H, Estey E, et al. Treatment of Waldenstrom macroglobulinemia with 2-chlorodeoxyadenosine. Ann Intern Med 1993;118:195-198.
18. Foran JM, Rohatiner AZ, Coiffier B, et al. Multicenter phase II study of fludarabine phosphate for patients with newly diagnosed lymphoplasmacytoid lymphoma, Waldenströms macroglobulinemia, and mantle-cell lymphoma. J Clin Oncol 1999;17:546-553.
19. Fridrik MA, Jager G, Baldinger C, Krieger O, Chott A, Bettelheim P. First-line treatment of Waldenströms disease with cladribine. Arbeitsgemeinschaft Medikamentö se Tumortherapie. Ann Hematol 1997;74:7-10.
20. Hellmann A, Lewandowski K, Zaucha JM, Bieniaszewska M, Halaburda K, Robak T. Effect of a 2-hour infusion of 2- chlorodeoxyadenosine in the treatment of refractory or previously untreated Waldenströms macroglobulinemia. Eur J Haematol 1999;63:35-41.
21. Thalhammer-Scherrer R, Geissler K, Schwarzinger I, et al. Fludarabine therapy in Waldenströms macroglobulinemia. Ann Hematol 2000;79:556-559.
22. Weber DM, Dimopoulos MA, Delasalle K, Rankin K, Gavino M, Alexanian R. 2-Chlorodeoxyadenosine alone and in combination for previously untreated Waldenstroms macroglobulinemia. Semin Oncol 2003;30:243-247.
23. Leblond V, Levy V, Maloisel F, et al.Multicenter, randomized comparative trial of fludarabine and the combination of cyclophosphamide-doxorubicin- prednisone in 92 patients with Waldenström macroglobulinemia in first relapse or with primary refractory disease. Blood 2001;98:2640-2644.
24. Dimopoulos MA, Hamilos G, Efstathiou E, et al. Treatment of Waldenstroms macroglobulinemia with the combination of fludarabine and cyclophosphamide. Leuk Lymphoma 2003; 44:993-996.
25. Kimby E, Treon SP, Anagnostopoulos A, et al. Update on recommendations for assessing response from the Third International Workshop on Waldenstroms Macroglobulinemia. Clin Lymphoma Myeloma 2006;6:380-383.
26. Tam CS, Wolf M, Westerman D, Januszewicz EH, Prince HM, Seymour JF. Fludarabine combination therapy is highly effective in first-line and salvage treatment of patients with Waldenströms macroglobulinemia. Clin Lymphoma Myeloma 2005;6:136-139.
27. Tamburini J, Levy V, Chaleteix C, et al. Fludarabine plus cyclophosphamide in Waldenstroms macroglobulinemia: results in 49 patients. Leukemia 2005;19:1831-1834.
28. Tedeschi A, Miqueleiz S, Ricci F, et al. Fludarabine, cyclophosphamide and rituximab in Waldenstroms macroglobulinemia: an effective regimen requiring a new category of response criteria and a delayed assessment of results. Blood 2007;110(Suppl. 1): Abstract 1290.
29. Tedeschi A, Alamos SM, Ricci F, Greco A, Morra E. Fludarabine-based combination therapies for Waldenströms macroglobulinemia. Clin Lymphoma Myeloma 2009;9:67-70.
30. Treon SP, Branagan AR, Ioakimidis L, et al. Long-term outcomes to fludarabine and rituximab in Waldenstrom macroglobulinemia. Blood 2009;113:3673-3678.
31. Vargaftig J, Pegourie-Bandelier B, Mahe B, et al. Fludarabine plus cyclophosphamide and rituximab (RFC) in Waldenstroms macroglobulinemia (WM): results in 25 patients. Haematologica 2007;92(Suppl. 2): Abstract 1226.
32. Vargaftig J, Pegourie-Bandelier B, Mahe B, et al. Fludarabine plus cyclophosphamide and rituximab (RFC) in Waldenstroms macroglobulinemia (WM): results in 21 patients (pts). Blood 2006;108(Suppl. 1): Abstract 4727.
33. Thomas SK, Delasalle K, Gavino M, Wang M, Alexanian R, Weber DM. 2-CDA-cyclophosphamide+rituximab for symptomatic WM. Haematologica 2007;92(Suppl. 2): Abstract 1227.
34. Laurencet FM, Zulian GB, Guetty-Alberto M, Iten PA, Betticher DC, Alberto P. Cladribine with cyclophosphamide and prednisone in the management of low-grade lymphoproliferative malignancies. Br J Cancer 1999;79:1215-1219.
35. Van Den Neste E, Louviaux I, Michaux JL, et al. Phase I/II study of 2-chloro-20-deoxyadenosine with cyclophosphamide in patients with pretreated B cell chronic lymphocytic leukemia and indolent non-Hodgkins lymphoma. Leukemia 2000;14:1136-1142.
36. Dimopoulos MA, Anagnostopoulos A, Kyrtsonis M-C, et al. Primary treatment of Waldenstrom macroglobulinemia with dexamethasone, rituximab, and cyclophosphamide. J Clin Oncol 2007;25:3344-3349.
37. Treon SP, Ioakimidis L, Soumerai JD, et al. Primary therapy of Waldenstrom macroglobulinemia with bortezomib, dexamethasone, and rituximab: WMCTG Clinical Trial 05-180. J Clin Oncol 2009;27:3830-3835.
38. Treon SP, Soumerai JD, Branagan AR, et al. Thalidomide and rituximab in Waldenstrom macroglobulinemia. Blood 2008;112:4452-4457.
39. Michallet M, Thiébaut A, Dreger P, et al. Peripheral blood stem cell (PBSC) mobilization and transplantation after fludarabine therapy in chronic lymphocytic leukaemia (CLL): a report of the European Blood and Marrow Transplantation (EBMT) CLL subcommittee on behalf of the EBMT Chronic Leukaemias Working Party (CLWP). Br J Haematol 2000;108:595-601.
40. Tournilhac O, Cazin B, Lepretre S, et al. Impact of frontline fludarabine and cyclophosphamide combined treatment on peripheral blood stem cell mobilization in B-cell chronic lymphocytic leukemia. Blood 2004;103:363-365.
41. Leleu X, Soumerai J, Roccaro A, et al. Increased incidence of transformation and myelodysplasia/acute leukemia in patients with Waldenstrom macroglobulinemia treated with nucleoside analogs. J Clin Oncol 2009;27:250-255.